Loading stock data…
Sanofi engages in the research (SNY)
$43.35-0.01 (-0.02%)
Market ClosedLast close Jul 24
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sanofi in the Healthcare sector is trading at $43.35 with a market capitalization of $104.8B. Wall Street consensus targets $55.06 (9 analysts), implying a +27.0% move over the next 12 months. The stock is currently 18% below its 52-week high of $52.68, remaining 3.3% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +27.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.24B↓ | $12.21B↓ | $13.17B↑ | $10.73B↑ | $10.61B |
| Gross Profit | $8.11B↓ | $8.45B↓ | $9.76B↑ | $7.74B↑ | $7.72B |
| Operating Income | $2.27B↑ | $1.63B↓ | $3.79B↑ | $1.71B↓ | $2.23B |
| Net Income | $1.61B↑ | -$801.00M↓ | $2.80B↓ | $3.94B↑ | $1.87B |
Peer Comparison
JNJUNHPFE
Fundamentals
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$104.75B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.38%
Volume
Today's trading volume
3.06M
Recent News
Sanofi (ENXTPA:SAN) Stops Amlitelimab In Eczema And Expands Aqemia AI Pact
Sanofi discontinued clinical development of amlitelimab in atopic dermatitis, citing efficacy and safety assessments. The company expanded its AI driven drug discovery collaboration with Aqemia to pursue new drug candidates. Both decisions affect Sanofi's dermatology pipeline and its approach to using generative AI in R&D. Sanofi (ENXTPA:SAN), trading at around €76.03, is adjusting its research focus as it pulls amlitelimab from atopic dermatitis trials and leans further into AI supported...
Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO
Gene-editing biotech debuts at $25, backed by Sanofi and Eli Lilly, with a roughly $440.3 million valuation.
Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO
(Bloomberg) -- Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering.Most Read from BloombergRetina Chip Designed to Restore Sight to Go on Sale in EuropeHegseth Turns to UNC, Virginia Tech After Dropping Ivy LeagueApple Plans Overhaul of MacBooks, iMac in Push to Meet AI DemandTrump Rebuilds Tariffs With New Levies on 60 EconomiesSpaceX Turns Away Falcon Customers in Majo
Sanofi abandons eczema drug approval efforts in another blow to OX40 class
While amlitelimab elicited durable responses in AD, Sanofi does not believe the drug is meaningfully differentiated from current eczema treatment offerings.
Update: US Equity Futures Nudge Higher Pre-Bell as Traders Weigh New US Tariffs, Declining Oil Prices
(Updates with economic data, recent oil price movement, world markets' overview and corporate stock